ICU Medical, Inc. (NASDAQ:ICUI) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $192.80.

A number of brokerages have recently commented on ICUI. BTIG Research lifted their target price on shares of ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, August 7th. Needham & Company LLC increased their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. KeyCorp increased their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Finally, Piper Sandler boosted their target price on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, August 7th.

Insider Buying and Selling

In other news, VP Daniel Woolson sold 5,417 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the transaction, the vice president directly owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the completion of the sale, the insider directly owned 3,076 shares of the company’s stock, valued at $548,512.32. This represents a 42.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 in the last ninety days. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently made changes to their positions in ICUI. Allworth Financial LP acquired a new stake in ICU Medical in the second quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new position in ICU Medical during the fourth quarter worth about $32,000. Versant Capital Management Inc raised its position in ICU Medical by 26.2% during the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 65 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of ICU Medical in the second quarter valued at about $51,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Trading Up 2.0%

Shares of ICU Medical stock opened at $160.32 on Monday. The company has a fifty day simple moving average of $168.41 and a 200-day simple moving average of $148.25. ICU Medical has a 12-month low of $112.50 and a 12-month high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.01 billion, a price-to-earnings ratio of 135.86, a PEG ratio of 1.98 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities analysts forecast that ICU Medical will post 7.22 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company’s product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.